title: Emerging biological agents for hepatitis C.
abstract: BACKGROUND
  New direct-acting antiviral agents have changed the landscape of treatment of chronic HCV infection. Despite current treatments are well tolerated with a high rate of sustained virological response (SVR), some medical needs remain. Nowadays there are a large number of approved medications for the treatment of HCV infection; nevertheless, new studies are conducted to find new agents and new combinations.
  
  
  METHODS
  A literature research of new antiviral compounds indicated for the treatment of HCV infection was achieved by an online search of medication undergoing development on Pubmed and clinicalTrials.gov clinical trials registry. We considered phase I/II studies and some randomized Phase III trials.
  
  
  CONCLUSIONS
  More knowledge about impact of HCV eradication on disease progression and more confidence regarding drug-drug interaction are needed. Furthermore, each treatment should be individualized targeting the patients needs with the aim not only to obtain viral suppression but also to stop progression of liver disease and HCV related conditions, and to improve patient health status.
authors.affiliation: a Dipartimento Malattie infettive , Fondazione IRCCS Policlinico San Matteo Pavia , Pavia , Italia.
authors.forename: Valentina
authors.initials: V
authors.lastname: Zuccaro
authors.affiliation: a Dipartimento Malattie infettive , Fondazione IRCCS Policlinico San Matteo Pavia , Pavia , Italia.
authors.forename: Paola
authors.initials: P
authors.lastname: Columpsi
authors.affiliation: a Dipartimento Malattie infettive , Fondazione IRCCS Policlinico San Matteo Pavia , Pavia , Italia.|b University of Pavia - Medical School- Harvey Course , Pavia , Italy.
authors.forename: Alice
authors.initials: A
authors.lastname: Apollinari
authors.affiliation: a Dipartimento Malattie infettive , Fondazione IRCCS Policlinico San Matteo Pavia , Pavia , Italia.
authors.forename: Paolo
authors.initials: P
authors.lastname: Sacchi
authors.affiliation: a Dipartimento Malattie infettive , Fondazione IRCCS Policlinico San Matteo Pavia , Pavia , Italia.
authors.forename: Marco
authors.initials: M
authors.lastname: Mussa
authors.affiliation: a Dipartimento Malattie infettive , Fondazione IRCCS Policlinico San Matteo Pavia , Pavia , Italia.
authors.forename: Andrea
authors.initials: A
authors.lastname: Schimmenti
authors.affiliation: c U.S.C. Gastroenterologia Epatologia e Trapiantologia Dipartimento di Medicina Specialistica e dei Trapianti Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII Bergamo , Bergamo , Italia.
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Lucà
authors.affiliation: b University of Pavia - Medical School- Harvey Course , Pavia , Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Fagiuoli
authors.affiliation: a Dipartimento Malattie infettive , Fondazione IRCCS Policlinico San Matteo Pavia , Pavia , Italia.|d Dipartimento di Scienze Clinico , Chirurgiche Diagnostiche e Pediatriche Università degli Studi di Pavia , Pavia , Italia.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Bruno
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001685:Biological Factors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018450:Disease Progression; D015195:Drug Design; D004347:Drug Interactions; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016032:Randomized Controlled Trials as Topic
chemical_list: D000998:Antiviral Agents; D001685:Biological Factors
keywords: DAA’s; HCV; direct antiviral agents; therapy